Oncolytics Biotech (ONCY) Assets Average (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Assets Average of $9.3 million for Q4 2025, down 42.54% year-over-year from $16.1 million in Q4 2024, and down 26.95% quarter-over-quarter from $12.7 million in Q3 2025.
Oncolytics Biotech (ONCY) Assets Average (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Assets Average for 17 consecutive years, with $9.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 42.54% year-over-year to $9.3 million; the TTM figure through Dec 2025 stood at $9.3 million (down 42.54% YoY), while the FY2025 annual figure was $10.5 million, down 50.22% from the prior year.
- Assets Average fell to $9.3 million in Q4 2025 per ONCY's latest filing, from $12.7 million in the prior quarter.
- Across five years, Assets Average topped out at $44.3 million in Q2 2021 and bottomed at $9.3 million in Q4 2025.
- Historically, Assets Average has averaged $27.1 million across 5 years, with a median of $27.9 million in 2022.
- Annual changes were most pronounced in 2021 — Assets Average soared 39.86% — and 2024, when it sank 48.75%.
- Oncolytics Biotech's Assets Average stood at $39.1 million in 2021, then dropped by 26.61% to $28.7 million in 2022, then rose by 9.62% to $31.4 million in 2023, then tumbled by 48.75% to $16.1 million in 2024, then sank by 42.54% to $9.3 million in 2025.
- Business Quant data shows ONCY's Assets Average at $9.3 million in Q4 2025, $12.7 million in Q3 2025, and $14.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | Oncolytics Biotech | 98.70 Mn | 98.70 Mn | - | 7.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.63 Mn |
| Dec 31, 2025 | 9.26 Mn |
| Sep 30, 2025 | 12.68 Mn |
| Jun 30, 2025 | 14.07 Mn |
| Mar 31, 2025 | 14.09 Mn |
| Dec 31, 2024 | 16.12 Mn |
| Sep 30, 2024 | 20.62 Mn |
| Jun 30, 2024 | 24.62 Mn |
| Mar 31, 2024 | 27.15 Mn |
| Dec 31, 2023 | 31.45 Mn |
| Sep 30, 2023 | 29.09 Mn |
| Jun 30, 2023 | 24.96 Mn |
| Mar 31, 2023 | 26.82 Mn |
| Dec 31, 2022 | 28.69 Mn |
| Sep 30, 2022 | 30.72 Mn |
| Jun 30, 2022 | 33.33 Mn |
| Mar 31, 2022 | 35.74 Mn |
| Dec 31, 2021 | 39.09 Mn |
| Sep 30, 2021 | 43.79 Mn |
| Jun 30, 2021 | 44.31 Mn |